US FDA Wants Authority To Mandate Minor Post-Approval Quality Changes

Legislative proposal in FY 2020 budget request wouldn't necessarily reduce number of complete response letters, but ability to require reports and postmarket changes on quality issues might eventually create more flexibility during initial product reviews.